Role of Jak3 in Anaplastic Large Cell Lymphoma

Jak3 在间变性大细胞淋巴瘤中的作用

• 批准号: 7468066
• 负责人: HESHAM M AMIN
• 金额: $ 13.61万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-09-01 至 2011-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7468066
• 关键词: 2p23; Affect; Agar; Age; Agreement; Apoptosis; Appendix; Applications Grants; Biology; Blood; Cancer Biology; Cancer Center; Cell Cycle Arrest; Cell Line; Cell Survival; Cells; Child; Chromosomal translocation; Chromosome abnormality; Chromosomes; Clinic; Data; Development; Disease; Doctor of Medicine; Dominant-Negative Mutation; Down-Regulation; Elements; Enzymes; Equilibrium; Foundations; Gene Targeting; Genes; Goals; Growth; Human; Immunophenotyping; Interleukin 2 Receptor Gamma; Interleukin-15; Interleukin-2; Interleukin-7; Interleukin-9; Interleukins; Janus kinase 3; Ki-1 Large-Cell Lymphoma; Knowledge; Large-Cell Lymphomas; Lymphoma; Malignant Neoplasms; Manuscripts; Mediating; Mentors; Mission; Non-Hodgkin' s Lymphoma; Null Lymphocytes; Numbers; Oncogenes; Oncogenic; Pathogenesis; Patients; Phosphoric Monoester Hydrolases; Phosphotransferases; Physicians; Physiological; Play; Primary Neoplasm; Protein Tyrosine Kinase; Public Health; Publications; Relapse; Research; Research Personnel; Role; Sampling; Scientist; Signal Transduction; Solid; Staining method; Stains; Survival Rate; Testing; Therapeutic; Transfection; Translating; Treatment Protocols; Tumor Cell Line; Tyrosine Kinase Domain; anaplastic lymphoma kinase; base; cancer type; career; clinically significant; inhibitor/antagonist; insight; interleukin 9 receptor; neutralizing antibody; novel therapeutics; nucleophosmin; programs; promoter; receptor; research study; skills; src Homology Region 2 Domain; t(2; 5)(p23; q35); therapeutic target; tumor; tumorigenesis; young adult

DESCRIPTION (provided by applicant): Project Summary: The overall goal of this grant application is to acquire the opportunity to develop the knowledge and skills to become an independent physician-scientist who effectively translates bench studies to the clinic. Establishing a solid research foundation is one of the key elements with this approach. Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma (ALK+ ALCL) is an aggressive malignant lymphoma of T/null-cell immunophenotype. It frequently affects children and young adults, and an estimated 40-50% of the patients fail current therapeutics. Janus kinase 3 (Jak3) is a protein tyrosine kinase with biologic functions related to cell survival and tumorigenesis. Our preliminary studies showed that Jak3 is constitutively activated in ALK+ ALCL cell lines and that inhibition of Jak3 decreases cell viability due to apoptosis and cell cycle arrest. Our preliminary studies also showed that Jak3 and ALK are physically associated and that inhibition of Jak3 decreases ALK kinase activity. Further, we found that ALK+ ALCL patients with tumors expressing activated Jak3 tend to have a lower survival rate than in ALK+ ALCL patients with tumors lacking the expression of activated Jak3. In addition, we demonstrated that IL-9 contributes to Jak3 activation by showing that IL-9 receptor-( and IL-9 are expressed in ALK+ ALCL cell lines and in most human primary tumors. Moreover, an anti-IL-9 neutralizing antibody decreased levels of activated Jak3 in and soft agar colony formation of ALK+ ALCL cells. Our preliminary studies also demonstrated that a major physiologic inhibitor of Jak3, SHP1, is absent or gene methylated in ALK+ ALCL cell lines and in most human tumors. Transfection of SHP1 into ALK+ ALCL cells induced downregulation of activated Jak3 levels. On the basis of these results, we hypothesize that constitutive activation of Jak3 by multilevel dysregulation plays an important role in the pathogenesis of ALK+ ALCL. The specific aims of this proposal are to 1) define the pathogenetic role of Jak3 in ALK+ ALCL and 2) establish the biologic and clinical significance of Jak3 activation in tumors from ALK+ ALCL patients. The global aim of the proposed studies is to identify Jak3 as a potential therapeutic target in ALK+ ALCL patients; this aim is in complete agreement with the mission of M.D. Anderson Cancer Center of bringing novel therapeutics to the clinic. The balanced program of mentored research and career development proposed in this application will provide the applicant with a solid foundation for a successful career as an independent investigator in cancer biology. Relevance to public health: ALK+ ALCL is an aggressive type of cancer that commonly affects children and young adults. Our preliminary results showed that the enzyme Jak3 plays an important role in the development and progression of ALK+ ALCL. The direct aim of the proposed studies is to validate Jak3 as a therapeutic target in patients afflicted with this dreadful disease.

描述（由申请人提供）： 项目摘要：本拨款申请的总体目标是获得发展知识和技能的机会，成为一名独立的医师科学家，有效地将实验室研究转化为临床。建立坚实的研究基础是这种方法的关键要素之一。间变性淋巴瘤激酶阳性间变性大细胞淋巴瘤 (ALK+ ALCL) 是一种 T/无效细胞免疫表型的侵袭性恶性淋巴瘤。它经常影响儿童和年轻人，估计 40-50% 的患者目前的治疗失败。 Janus 激酶 3 (Jak3) 是一种蛋白酪氨酸激酶，具有与细胞存活和肿瘤发生相关的生物学功能。我们的初步研究表明，Jak3 在 ALK+ ALCL 细胞系中持续激活，抑制 Jak3 会因细胞凋亡和细胞周期停滞而降低细胞活力。我们的初步研究还表明，Jak3 和 ALK 在物理上相关，抑制 Jak3 会降低 ALK 激酶活性。此外，我们发现肿瘤表达活化 Jak3 的 ALK+ ALCL 患者的生存率往往低于肿瘤缺乏活化 Jak3 表达的 ALK+ ALCL 患者。此外，我们通过证明 IL-9 受体和 IL-9 在 ALK+ ALCL 细胞系和大多数人类原发性肿瘤中表达，证明 IL-9 有助于 Jak3 激活。此外，抗 IL-9 中和抗体ALK+ ALCL 细胞中活化的 Jak3 水平和软琼脂集落形成降低 我们的初步研究还表明，ALK+ 中不存在 Jak3 的主要生理抑制剂 SHP1 或基因甲基化。 ALCL 细胞系和大多数人类肿瘤中，将 SHP1 转染到 ALK+ ALCL 细胞中会诱导激活的 Jak3 水平下调。根据这些结果，我们推测 Jak3 的多级失调引起的组成性激活在 ALK+ ALCL 的发病机制中发挥着重要作用。该提案的具体目标是 1) 定义 Jak3 在 ALK+ ALCL 中的致病作用，以及 2) 建立ALK+ ALCL 患者肿瘤中 Jak3 激活的生物学和临床意义。拟议研究的全球目标是确定 Jak3 作为 ALK+ ALCL 患者的潜在治疗靶点；这一目标与 M.D. 安德森癌症中心将新型疗法引入临床的使命完全一致。本申请中提出的指导研究和职业发展的平衡计划将为申请人作为癌症生物学独立研究者的成功职业生涯提供坚实的基础。与公共卫生的相关性：ALK+ ALCL 是一种侵袭性癌症，通常影响儿童和年轻人。我们的初步结果表明酶 Jak3 在 ALK+ ALCL 的发生和进展中发挥着重要作用。拟议研究的直接目的是验证 Jak3 作为患有这种可怕疾病的患者的治疗靶点。

项目成果

Inhibition of IGF-IR tyrosine kinase induces apoptosis and cell cycle arrest in imatinib-resistant chronic myeloid leukaemia cells.

• DOI: 10.1111/j.1582-4934.2009.00795.x
• 发表时间: 2010-06
• 期刊: Journal of cellular and molecular medicine
• 影响因子: 5.3
• 作者: Shi P;Chandra J;Sun X;Gergely M;Cortes JE;Garcia-Manero G;Arlinghaus RB;Lai R;Amin HM
• 通讯作者: Amin HM